The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

In a report released today, Myles Minter from William Blair maintained a Hold rating on Moderna. The company’s shares closed last Thursday at $30.49. Don’t Miss TipRanks’ Ha ...

Many Indian firms chase quick returns, rely on imported technology, and underinvest in research. But innovation needs ...

Alkaline. Electrolyte. Flavored. Walk down the beverage aisle and you'll find all kinds of waters promising extra health ...

HHS Secretary Robert F. Kennedy Jr. was on The Tucker Carlson Show last week. It got me to thinking: What's next in RFK Jr.'s ...

Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In ...